Home › Compare › LZENF vs ABBV
LZENF yields 2000000.00% · ABBV yields 3.09%● Live data
📍 LZENF pulled ahead of the other in Year 1
Combined, LZENF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LZENF + ABBV for your $10,000?
Lizhan Environmental Corporation, through its subsidiaries, engages in the manufacture, distribution, marketing, and export of synthetic leather and other fabrics from leather scrap products and other materials in the People's Republic of China. It offers various synthetic leather fabric products, including ultrasuede products, recycled leather flocked fabrics, microfiber towel fabrics, tufted fabrics, and colgre products, as well as other fabrics consisting of flocking powder, suede fabrics, short hair velvets, and beehive punched cotton. The company is also involved in research and development related to the production of synthetic leather. Its products are used in various consumer applications, including residential and office furniture, garments, and automotive upholstery products. The company sells its products primarily to furniture manufacturers, as well as to fabric distributors. It exports its products to the United States, Nicaragua, Germany, Belgium, France, and South Korea. The company was founded in 2005 and is headquartered in Tongxiang, the People's Republic of China.
Full LZENF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.